60 Degrees Pharmaceuticals (SXTP) Receivables - Net (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Receivables - Net of $335836.0 for Q1 2026, down 31.22% year-over-year from $488243.0 in Q1 2025, and down 34.1% quarter-over-quarter from $509644.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Receivables - Net (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Receivables - Net for 5 consecutive years, with $335836.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net fell 31.22% year-over-year to $335836.0; the TTM figure through Mar 2026 stood at $335836.0 (down 31.22% YoY), while the FY2025 annual figure was $509644.0, up 4.7% from the prior year.
- Receivables - Net declined to $335836.0 in Q1 2026 per SXTP's latest filing, from $509644.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $674036.0 in Q3 2025 and bottomed at $45965.0 in Q4 2022.
- Historically, Receivables - Net has averaged $328209.9 across 5 years, with a median of $316220.0 in 2024.
- Annual changes were most pronounced in 2023 — Receivables - Net soared 403.28% — and 2026, when it sank 31.22%.
- 60 Degrees Pharmaceuticals' Receivables - Net stood at $45965.0 in 2022, then jumped by 403.28% to $231332.0 in 2023, then soared by 110.41% to $486748.0 in 2024, then rose by 4.7% to $509644.0 in 2025, then plunged by 34.1% to $335836.0 in 2026.
- Business Quant data shows SXTP's Receivables - Net at $335836.0 in Q1 2026, $509644.0 in Q4 2025, and $674036.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - |
| 10 | 60 Degrees Pharmaceuticals | 3.03 Mn | 2.00 Mn | 56,798.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 335,836.00 |
| Mar 31, 2026 | 335,836.00 |
| Dec 31, 2025 | 509,644.00 |
| Dec 31, 2025 | 509,644.00 |
| Sep 30, 2025 | 674,036.00 |
| Sep 30, 2025 | 674,036.00 |
| Jun 30, 2025 | 295,034.00 |
| Jun 30, 2025 | 295,034.00 |
| Mar 31, 2025 | 488,243.00 |
| Mar 31, 2025 | 488,243.00 |
| Dec 31, 2024 | 486,748.00 |
| Dec 31, 2024 | 486,748.00 |
| Sep 30, 2024 | 323,822.00 |
| Sep 30, 2024 | 323,822.00 |
| Jun 30, 2024 | 296,370.00 |
| Jun 30, 2024 | 296,370.00 |
| Mar 31, 2024 | 316,220.00 |
| Mar 31, 2024 | 316,220.00 |
| Dec 31, 2023 | 231,332.00 |
| Dec 31, 2023 | 231,332.00 |